Biogen (BIIB)
(Delayed Data from NSDQ)
$230.63 USD
+4.89 (2.17%)
Updated Jun 12, 2024 04:00 PM ET
After-Market: $230.48 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
Brokerage Reports
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 201 - 220 ( 804 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 5/27/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 6122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 5/20/22
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 5/13/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 5/6/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
What Comes Next with New CEO in the Post-Aduhelm World for Biogen?
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
First Take: Cost-Cutting Measures Escalate, CEO Transition
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Life After Aduhelm: Near-Term May Not Be All That Different
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Commercial Biotech Preview: Let''s Get It Over With
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Weekly Neurology Prescription Sales Tracker
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department